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Abstract: Protein tyrosine kinases (PTKs) play a pivotal role in signal transduction pathways and in the development and 
maintenance of various cancers. They are involved in multiple processes such as transcription, cell cycle progression, pro-
liferation, angiogenesis and inhibition of apoptosis. Among the PTKs, the EGFR is one of the most widely studied and has 
emerged as a promising key target for the treatment of cancer. Indeed, several drugs directed at this receptor are FDA-
approved and many others are at various stages of development. However, thus far, the therapeutic outcome of EGFR-
targeted therapy is suboptimal and needs to be refined. Quantitative PET molecular imaging coupled with selective la-
belled biomarkers may facilitate in vivo EGFR-targeted drug efficacy by noninvasively assessing the expression of EGFR 
in tumor, guiding dose and regime by measuring target drug binding and receptor occupancy as well as potentially detect-
ing the existence of a primary or secondary mutation leading to either drug interaction or failure of EGFR recognition by 
the drug. This review describes the attempts to develop labelled EGFR molecular imaging agents that are based either on 
low molecular weight tyrosine kinase inhibitors or monoclonal antibodies directed to the extracellular binding domain of 
the receptor to be used in nuclear medicine modalities.  
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INTRODUCTION 
  In 2005, deaths attributed to cancer reached 7.5 millions 
worldwide, and the number of diagnosed cases is postulated 
to gradually increase and reach about 20 million in 2020 [1]. 
The battle to combat this deadly disease was initiated in the 
late 1940's with the introduction of the first chemotherapeu-
tic agents. These non-specific agents predominantly affect 
hyper-proliferating cells, characteristic of many cancers, and 
exert their cytotoxic effects through different pharmacologi-
cal modes of action, including induction of DNA damage, 
inhibition of RNA and DNA synthesis, and/or disruption of 
the cytoskeleton. The significant contribution to cancer man-
agement due to the institution of such chemotherapeutic 
agents cannot be overestimated. Nonetheless, the overall 
toxicities and side effects of these drugs limit the dose re-
gime resulting in a narrow therapeutic index and, in most 
cases the produced responses are insufficient and unpredict-
able. Furthermore, during the course of therapy, cross-
resistance to different chemotherapeutic drugs can be associ-
ated with recurrence of the disease [2-4].  
  In the late 1980's, improved and more specific appro- 
aches for treating cancer emerged by virtue of a plethora of 
chemical and biochemical technologies. One such valid ap-
proach involves various strategies that specifically interfere 
with crucial signaling pathways which are dysregulated in 
malignant cells and play a pivotal role in the development 
and maintenance of various cancers. Much effort within this 
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approach has focused on the inhibition of protein tyrosine 
kinases (PTKs). There are approximately 20 classes of 
PTKs, including the epidermal growth factor (EGF), insulin, 
PDGF, FGF, VEGF, and HGF receptor families [5]. The 
EGF family (receptor tyrosine kinase class I) of membrane 
receptors, also called human epidermal receptor (HER) fam-
ily, is one of the most relevant targets in this class. There are 
four closely related receptors in this family [6]: EGFR 
(HER1,  erbB1), HER2 (neu,  erbB2), HER3 (erbB3), and 
HER4 (erbB4). Ligands include EGF, amphiregulin, and 
TGF- for EGFR, and a group of differentiation factors 
called neuregulins for HER3 and HER4. Heparin-binding 
EGF, betacellulin, and epiregulin can stimulate EGFR and 
HER4. In all cases, ligand binding is followed by formation 
of receptor homo- or heterodimers. HER2 is unique in that it 
has no specific ligand and is locked constitutively in a con-
formation resembling the ligand-bond states. As such, it is 
subject to heterodimerization with other members of the ac-
tivated HER family. 
EPIDERMAL GROWTH FACTOR RECEPTOR 
(EGFR) 
  EGFR (170 kDa) is a membrane-spanning glycoprotein 
and consists of an extracellular ligand-binding domain, a 
transmembrane domain, and an intracellular domain with 
tyrosine kinase activity. Binding of ligand induces the di-
merization of receptors, followed by activation of the cyto-
plasmic tyrosine kinase domain and the subsequent signal 
transduction cascade. Signal termination occurs mainly by 
endocytosis of the activated receptor [7, 8]. EGFR is associ-
ated
  with oncogenic transformation, and dysregulation of 2984    Current Pharmaceutical Design, 2008, Vol. 14, No. 28  Mishani et al. 
EGFR
 is associated with all of the key features of cancer [8]. 
An increased expression of EGFR is the hallmark of many 
human tumors such as breast cancer, squamous cell carci-
noma of the head and neck, and prostate cancer (Table 1).  
PTKs AS TARGETS FOR CANCER THERAPY 
  PTKs catalyze the transfer of phosphate in ATP to spe-
cific tyrosine residues within proteins, thereby altering their 
structure and function. They play a crucial role in signal 
transduction pathways that control both intracellular signal-
ing and intercellular communication and are involved in 
multiple processes such as metabolism, transcription, cell 
cycle progression, cytoskeletal rearrangement and cell move- 
ment, proliferation, angiogenesis and inhibition of apoptosis. 
Of the 91 PTKs identified thus far, 59 are receptor TKs, and 
32 are cellular TKs, most of them regulating signaling which 
is crucial for normal cell development and survival. Since 
PTKs hold a key position in the function of multicellular 
organisms, it is not surprising that PTK malfunction can lead 
to conditions such as psoriasis, cardiovascular disease, athe-
rosclerosis and cancer. Most diseases involve PTK dysregu-
lation owing to: a) overexpression of TK receptor and its 
ligand or both resulting in autocrine-paracrine stimulation; b) 
dimerization of a PTK receptor or a cellular PTK with a re-
lated protein; c) various mutations in the PTK itself, leading 
to enhanced and sometimes persistent stimulation [9-12]. 
Approximately 50% of the known oncogenes encode PTKs 
[13, 14]. As a result, PTKs, whether receptors or cellular 
proteins have become valid targets to combat cancer through 
specific biochemical mechanisms meant to decrease side 
effects [15-25].  
  Receptor PTKs can be targeted by two classes of drugs 
[26]: in the first class, monoclonal antibodies (mAbs) target 
the extracellular binding domain (Fig. 1) [27], and inhibit 
cancer cell growth via several direct processes such as inter-
rupting PTK signaling in most cases by blockage of their 
ligand binding, inhibiting cell cycle progression or DNA 
repair, reducing angiogenesis, and inducing apoptosis, and 
Table 1.  EGFR Expression in Solid Tumors [6, 116] 
Tumor Type  Range of Tumors Expressing EGFR (%)  Tumor Type  Range of Tumors Expressing EGFR (%) 
Head and neck  80–100   Prostate  40–80 
Colorectal 25–77  Bladder  53–72 
Pancreatic 30–50  Cervical  54–74 
Lung 40–80 Ovarian  35–70 
Esophageal 71–88  Breast  14–91 
Renal cell  50–90  Glioblastoma  40–50 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1).  Mechanism of action of anti-EGFR mAb-based drugs. 
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via indirect processes mediated by the immune system such 
as complement-dependent cytotoxicity (CDC) and antibody-
dependent cellular cytotoxicity (ADCC) [26] . In the second 
class, low molecular weight TK inhibitors target the intracel-
lular ATP binding domain of the receptor [15]. Cellular 
PTKs are exclusively targeted by the latter class of drugs. 
One of the first PTK mAb inhibitors is the IgG1-class mono-
clonal antibody trastuzumab (Herceptin
®) (Table 2). Trastu-
zumab is an anti-erbB2 mAb which increases response rates 
and improves survival in patients with erbB2-overexpressing 
breast cancer when combined with conventional chemother-
apy [28, 29]. It is unique in that, unlike mAbs which target 
the EGFR, it is only active against cancers that overexpress 
its target, therefore erbB2 testing prior to treatment is man-
datory. Cetuximab is another IgG1 class mAb targeting the 
EGFR (Table 2). Surprisingly, although this mAb displays 
insufficient effect against EGFR-overexpressing breast can-
cer, it has yielded positive clinical results against head and 
neck cancers overexpressing the EGFR and has demon-
strated activity in colon cancer regardless of tumor EGFR 
expression [30-32]. The mechanisms of action of Cetuximab 
remain unknown, yet more disturbingly, is the inability to 
predict patient response. Panitumumab and Matuzumab are 
other anti-EGFR mAbs (Table 2). Panitumumab has a mod-
erate activity in primary and metastatic colorectal carcinoma 
with no evident correlation with tumor EGFR expression 
[33-35]. The clinical results of Matuzumab in colorectal can-
cer are suboptimal and the drug is currently undergoing 
phase II clinical trials for the treatment of lung and stomach 
cancer. Bevacizumab is an anti VEGF mAb which is used to 
suppress tumor growth through inhibition of angiogenesis. 
This drug was approved by the FDA for use in combination 
with standard chemotherapy in the treatment of metastatic 
colon cancer and all forms of metastatic non small cell lung 
cancer. Lately, it was approved by the FDA for the treatment 
of breast cancer. Although some of the above mentioned 
mAbs have become accepted drugs in clinical practice, cur-
rently there is no reliable clinical modality that would prop-
erly select responders and predict therapeutic outcome. 
However, a correlation between tumor response and skin 
toxicity has been found which may indicate that some pa-
tients not responding to treatment were "underdosed" [36, 
37]. 
  The second class of compounds is low molecular weight 
TK inhibitors which target the ATP binding domain of PTKs 
and disrupt the hyperactive signal transduction pathways in 
cancer cells. The first step in the development of low mo-
lecular weight PTK inhibitors began shortly following the 
recognition in the early 1980's that natural compounds such 
as quercetin, genistein, lavendustin, erbstatin and herbimycin 
A [38-43] are potent inhibitors of PTKs. Although these 
natural compounds have no selectivity and therefore were 
found to be very toxic, they served as starting templates for 
the design and development of synthetic, more potent and 
selective PTK inhibitors. The benzylidine moiety of erbstatin 
and other arylidene derivatives were developed into a class 
of PTK blockers defined as tyrphostins (tyrosine phosphori-
lation). The first group of PTK inhibitors synthesized was 
the benzene malononitrile tyrphostins [44-47]. These com-
pounds were competitive with the substrate and non com-
petitive with ATP. In the mid-1990's, when structure activity 
Table 2.  Protein Tyrosine Kinases (PTKs) Targeted Drugs 
Drug/Type PTKs  Indication 
Cetuximab (Erbitux)/ mAb erbB1  (EGFR)  colorectal cancer, phase III for head/neck, pancreatic  
cancers and NSCLC, Phase II for HCC 
Matuzumab (EMD 72000)/ mAb  erbB1 (EGFR)  phase I/II for NSCLC, ovarian, pancreatic cancer 
Panitumumab (ABX-EGF, Vectibix )/ mAb  erbB1 (EGFR)  colorectal cancer, phase I for refractory solid Tumors 
Erlotinib (Tarceva)TK inhibitor  erbB1 (EGFR)  NSCLC, pancreatic cancer, phase II for HCC 
Gefitinib (Iressa)/ TK inhibitor  erbB1 (EGFR)  NSCLC, phase I for HCC 
EKB-569/ TK inhibitor  erbB1 (EGFR)  phase II for advanced colorectal cancer and NSCLC 
Lapatinib (Tykerb)/ TK inhibitor  erbB1 (EGFR)/ erbB2  advanced metastatic breast cancer 
Canertinib (CI-1033)/TK inhibitor  Pan-erbB  phase II for SCC, ovarian and metastatic breast cancer cancer  
Trastuzumab (Herceptin)/ mAb erbB2  Breast  cancer 
Imatinib (Gleevec)/TK inhibitor  ABL, PGRFR, KIT  CML, CMML, CEL, GIST 
Bevacizumab (Avastin)*/ mAb  VEGF A  NSCLC, colorectal cancer 
Semaxanib (SU5416)/ TK inhibitor  VEGFR, EGFR, KIT  phase II for metastatic melanoma 
Sunitinib (Sutent)/ TK inhibitor  VEGFR, KIT, PDGFR, Flt3  GIST, Renal cell carcinoma 
Vatalanib/ TK inhibitor  VEGFR, PDGFR  phase III for colorectal and phase II for GIST, prostate and kidney cancer 
NSCLC, non small cell lung cancer; HCC, hepatocellular cancer; CML, Chronic myeloid leukemia; CMML, Chronic myelomonocytic leukemia; CEL, Chroniceosinophilic leu-
kemia; GIST, Gastrointestinal stromal tumor; SCC, Squamous cell carcinoma. 2986    Current Pharmaceutical Design, 2008, Vol. 14, No. 28  Mishani et al. 
led to bicyclic tyrphostins, the main thrust in the develop-
ment of PTK inhibitors was to endorse a generation of ATP 
competitive kinase inhibitors. The most common chemical 
structures of these tyrphostins are anilinoquinazolines, anili-
noquinolines and anilinopyridopirimidines.  
  Although ATP binding sites are highly conserved among 
tyrosine kinases, minor differences in kinase domain struc-
tures in combination with combinatorial chemistry, struc-
tured-based drug design and computational chemistry have 
led to the development of highly selective PTK inhibitors. In 
the past few years, over 30 inhibitors were at various stages 
of development. Clinical studies conducted recently have 
recognized some of these inhibitors as therapeutic drugs for 
specific cancers. Imatinib (STI-571;Gleevec) (Table 2, Fig. 
2) has been identified as an effective Bcr-Abl inhibitor with 
durable response in patients in the early phase of chronic 
myelogenous leukemia (CML) with minimal side effects [48, 
49]. Imatinib is also the standard of care, first-line treatment 
for unresectable or metastatic gastrointestinal stromal tumors 
[GIST] [50],  especially in patients who harbor activating 
mutations in c-Kit.  
  In the field of cancer angiogenesis, various VEGFR in-
hibitors are currently being evaluated in clinical trials, in-
cluding semaxanib and vatalanib (Table 2, Fig. 2). In clinical 
studies, vatalanib, which inhibits VEGFR-1 and -2, PDGFR 
and c-Kit, has been shown to suppress hepatocellular carci-
noma (HCC) growth and to have anti-neoplastic effects in 
other solid tumors [51, 52]. Sunitinib (Sutent, Table 2), an-
other promising agent against angiogenesis, inhibits the 
VEGFR as well as the PDGFR, c-KIT and Flt3 tyrosine 
kinases. Sunitinib has been approved for the treatment of 
renal cell carcinoma and for the treatment of GIST, and is 
currently tested in phase II trials for HCC [53, 54]. Most of 
these drugs produce limited response as monotherapeutic 
agents against solid tumors and are considered to be more 
effective in combination with other PTK drugs [55-59].  
  Three EGFR/erbB2 low molecular weight reversible in-
hibitors have thus far been approved for clinical use: la-
patinib, gefitinib and erlotinib (Table 2, Fig. 2), and numer-
ous other drug candidates are in various stages of develop-
ment. Gefitinib and erlotinib are more selective for the 
EGFR, while lapatinib targets both EGFR and erbB2. Prom-
ising results have been obtained using gefitinib and erlotinib 
in pre-clinical models of EGFR overexpressing cell lines and 
xenografts [60, 61]. Nonetheless, these results failed to re-
produce in the clinical setting since both agents appear to be 
effective only in the subset of NSCLC patients [62]. Higher 
response rates to gefitinib and erlotinib therapies have also 
been reported in patients with EGFR expressing tumors con-
taining well-defined activating mutations [63-67]. This 
higher sensitivity of the mutant form could be due to struc-
tural changes at the kinase domain mutation rendering the 
receptor more receptive to inhibitor binding. However, simi-
larly to imatinib, patients who initially responded to these 
treatments have occasionally developed therapy resistance 
due to acquired secondary mutation in the EGFR [68], thus, 
necessitating the acquisition of further clinical and experi-
mental data so as to better predict response to such therapies. 
More recent pre-clinical and clinical publications indicate 
that irreversible inhibitors of the EGFR such as Canertinib 
and EKB-569 (Fig. 2, Table 2) appear to circumvent this 
resistance suggesting that this category of inhibitors may 
benefit from a larger clinical application [68-72].  
  The concept of targeted therapies by specifically inhibit-
ing PTKs in cancer is very promising, albeit several drugs 
that have entered clinical trials have not yielded the predicted 
positive outcome. This inconsistency can be attributed to 
several factors working in unison or independently of each 
other including: inappropriate selection of potential respond-
ers in terms of the expression of the targeted protein in a 
particular tumor; insufficient inhibition of the targeted PTKs 
due to inappropriate dosage schedule; resistance due to a 
secondary mutation in the PTKs developed during therapy; 
loss of the survival factor role of the targeted PTKs in cancer 
cells during therapy, and the development of other pathways 
as a salvage and escape mechanism for cancer cell survival. 
One possible approach that may yield better results would be 
either to use multi-drug therapies working in synergy and 
meant to target several PTKs [15, 73], or drugs targeting 
multiple PTKs which play a major role in cancer cell prolif-
eration. Better yet, a reliable and accurate quantitative assay 
to determine PTK levels and their role in tumors is required 
to establish a customized targeted treatment [74].  
NUCLEAR MEDICINE AND PET MOLECULAR IM-
AGING OF EGFR 
  As tumor cells are characterized by uncontrolled prolif-
eration and enhanced cell growth, it has been observed that 
most tumor cells over-express one or several hormone recep-
tors [75]. Radiopharmaceuticals which selectively target 
those receptors can be used to diagnose and/or treat cancer. 
Molecular imaging of tumors via nuclear medicine modali-
ties such as single photon computed tomography (SPECT) or 
positron emission tomography (PET) using targeted radio-
pharmaceuticals, could visualize the underlying mechanism 
of cellular processes in vivo and complements and enhances 
anatomical information acquired by computed tomography 
(CT) and magnetic resonance imaging (MRI). PET is based 
on the administration of radioactively-labeled probes (radio-
pharmaceutical) with characteristic physiological or biologi-
cal properties. Following the administration of the probe, 
spatial and temporal monitoring of its biodistribution within 
the body is conducted using a PET scanner. To this end, the 
desired molecule (either natural or synthetic) is labeled with 
a positron-emitting isotope. Positrons (
+) travel only a few 
millimeters before they encounter an electron, which leads to 
the formation of two annihilation photons at a 180° angle. 
Simultaneous detection of these two 511 keV photons by the 
scanner forms the basis of PET imaging. The resolution of 
clinical PET scanners is in the low millimeter range, which 
is not as high as MRI (100–500 μm), but higher than that of 
the alternative method SPECT (3–6 mm). However modern 
PET/ CT scanners offer a more accurate anatomic localiza-
tion of radioactivity, thereby enhancing the interpretation of 
PET images. The superiority of nuclear medicine compared 
to other imaging modalities stems from its high sensitivity, 
in a nanomolar (nM) concentration-range, as opposed to mil-
limolar (mM) concentrations for other related imaging tech-
niques, thus enabling in vivo quantitative visualization of 
"low capacity systems" such as receptors and enzymes. After 
a tumor is diagnosed, a targeted radiopharmaceutical can be Imaging of EGFR and EGFR Tyrosine Kinase Overexpression  Current Pharmaceutical Design, 2008, Vol. 14, No. 28    2987 
used to determine the optimal therapy by identifying key 
molecular markers on the tumor cells. During the course of 
therapy, the radiopharmaceutical can be used to monitor 
early response to the chosen targeted treatment. 
  Immunohistochemistry (IHC) is the most frequently ap-
plied method for evaluating PTK expression in tumor tis-
sues, however, it requires tissue biopsies, which are not al-
ways available and furthermore, do not always represent the 
pathology of the whole tumor nor of distant, unexamined 
metastases. Additionally, IHC provides only semi-quantita- 
tive data, and can be inconsistent due to variations in meth-
odology [76]. Thus, many hurdles remain to be overcome in 
order to effectively treat various types of cancers by targeted 
PTK therapy. Molecular imaging such as PET coupled with 
suitable selective labeled bioprobes that target specific PTKs 
has the potential to resolve some of the above mentioned 
obstacles by: 1) noninvasively determining whether the tar-
get protein is expressed in a specific tumor and its metasta-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Chemical structure of PTKS drugs 
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sis; 2) monitoring target-drug binding and receptor occu-
pancy in vivo; 3) determining duration of PTK inhibition in 
vivo; and 4) potentially identifying the existence of a primary 
or secondary mutation leading to either drug interaction or 
loss of PTK recognition by the drug.  
  As demonstrated above, EGFR expression in tumors is 
not sufficient to predict EGFR targeted therapeutic response. 
However, in many cases, its overexpression in tumors is a 
prerequisite for initiating such treatment and can be meas-
ured non-invasively by molecular imaging modalities such 
as PET. Indeed, within the PTKs, most research has primar-
ily focused on EGFR as a target for PET imaging either by 
the development and acquisition of labeled monoclonal anti-
bodies directed to the extracellular binding domain or by the 
development of low molecular weight PET agents derived 
from the anilinoquinazoline skeleton of existing or potential 
drugs targeting the intracellular ATP binding domain of the 
receptor [77]. 
RADIOPHARMACEUTICALS FOR IMAGING EGFR 
EXPRESSION IN TUMORS 
Radiolabeled Intact mAbs for Imaging EGFR Expression 
in Tumors 
  The use of radiolabeled anti-EGFR antibodies for EGFR-
expressing cancer diagnosis has become the subject of in-
tense investigation as more mAbs with relevant and well-
characterized specificities become available. Anti-EGFR 
mAbs have been used and evaluated for imaging with a vari-
ety of radionuclides, including radiometals and radiohalo-
gens (Table 3). Cetuximab attached to the radiometal chela-
tor diethylenetriaminepentaacetic acid (DTPA) and labeled 
with 
111In was shown to localize specifically in tumors that 
over-express EGFR [78, 79]. However, a considerable 
amount of radioactivity in the liver was observed limiting the 
clinical usefulness of this agent for cancer imaging. An im-
proved cetuximab conjugate (DTPA-PEG-cetuximab) was 
reported to overcome this problem, as tumor imaging of 
111In-DTPA-PEG-cetuximab in nude mice showed signifi-
cant reduction of radioactivity in the liver using a gamma 
camera [79]. Although cetuximab Fab' and F(ab')2 fragments 
have been investigated, they have reduced binding affinity 
(5-fold weaker) and showed less inhibition of tumor growth 
than the intact antibody [80].  
 Perk et al., reported the biodistribution of positron-
emitting 
89Zr-deferrioxamine-cetuximab as a surrogate imag-
ing agent for therapy with 
90Y and/or 
177Lu-DOTA-cetuxi- 
mab [81]. Cetuximab-N-sucDf-
89Zr showed very comparable 
tumor uptake and clearance in non-target tissues to cetuxi-
mab-p-SCN-Bz-DTPA-
88Y (where gamma-emitting 
88Y was 
used for biodistribution studies) and cetuximab-p-SCN-Bz-
DTPA-
177Lu. The only difference in biodistribution was a 
higher uptake of cetuximab-N-sucDf-
89Zr in the bone, com-
pared to the 
88Y and 
177Lu-labeled agents.  
 Cai et al., reported the biodistribution of 
64Cu-DOTA-
cetuximab (Fig. 3) in seven different EGFR-expressing tu-
mor-bearing mouse models [82]. A correlation between 
EGFR expression by Western blot analysis and %ID/g in the 
various tumor types was observed, suggesting that 
64Cu-
DOTA-cetuximab is a potentially accurate biomarker for 
EGFR expression. In another study, Li et al. showed high 
uptake of 
64Cu-DOTA-cetuximab in A431 tumors, although 
there was significant uptake in the liver, in part due to 
64Cu 
dissociation from the DOTA chelator [83]. Improved chela-
tion systems for labeling 
64Cu to cetuximab will greatly im-
prove this agent for future human PET imaging studies.  
Radiolabeled Affibodies for Imaging EGFR Expression 
  Smaller molecular weight “affibodies” that bind to EGFR 
have been developed as alternatives to radiolabeled intact 
mAbs as imaging agents. Affibody molecules are three-helix 
bundle molecules based on 58 amino acids and are derived 
from the IgG-binding domains of staphylococcal protein A 
[84]. (ZEGFR: 955)2, a 14.6 kDa molecule, was selected from a 
phage display library consisting of 13 randomized residues, 
and binds to EGFR on cultured cells with low nanomolar 
affinity [85]. The smaller size compared to intact antibodies 
(~150 kDa) will allow greater tumor penetration and more 
rapid blood clearance. 
Table 3.  Decay Characteristics of Radionuclides Used to Label Anti-EGFR mAbs 
Isotope T1/2  
- MeV (max) (%)  
+ MeV (max) (%)   MeV (%) 
64Cu  12.7 h  0.573 (39.6%)  0.655 (17.4%)  0.51 (34.8%) 
88Y 108  d  -  - 
0.898 (91%) 
1.836 (100%) 
89Zr  78.4 h  -  0.9 (22%) 
0.511 (44%) 
0.91 (99%) 
1.71 (1%) 
111In 67.4  h  -  - 
0.173 (89%) 
0.247 (94%) 
125I  60.2 d  -  -  0.035 (7%) 
177Lu 6.74  d 
0.497 (90%) 
0.385 (3%) 
- 
0.113 (2.8%) 
0.208 (6.1%) Imaging of EGFR and EGFR Tyrosine Kinase Overexpression  Current Pharmaceutical Design, 2008, Vol. 14, No. 28    2989 
  The Affibody (ZEGFR: 955)2 was labeled with 
125I and com-
pared to 
125I-labeled EGF and cetuximab [84]. In A431 cells 
grown in culture, the uptake of 
125I-labeled (ZEGFR: 955)2 was 
more rapid than that of the other agents, and was found to be 
cell-associated for a longer time period, suggesting more 
rapid internalization and greater retention in EGFR-positive 
tumor cells. Affibody (ZEGFR: 955)2 was also labeled with 
111In, and in A431 tumor-bearing mice showed high tumor 
uptake, with tumor: blood ratios of 9.1 at 4 h post-injection 
[86]. 
 Additional  Affibody molecules were developed through 
the affinity maturation process and radiolabeled with 
111In 
[87] for evaluation in A431 tumor-bearing mice. All agents 
evaluated in tumor-bearing mice showed tumor uptake be-
tween 5-7% ID/g at 4 h post-injection with tumor: blood 
ratios of ~3. The kidney uptake was extremely high, how-
ever, with uptake ranging between 100-200 %ID/g.  
Low Molecular Weight Imaging Agents 
  Attempts to develop low-molecular weight imaging 
agents that target the TK domain of the EGFR have been 
mainly focused on the 4-anilinoquinazoline class of com-
pounds that has been originally developed for therapy. The 
reversible inhibitor PD 153035 was one of the first templates 
used for developing such molecular imaging agents. It was 
labeled with carbon-11 at the 7-methoxy position of the 
quinazoline ring (Fig. 4 ) and its biodistribution properties 
and specific uptake in the examined tissues have been inves-
tigated in non-tumor bearing mice [88]. Specific binding in 
these blocking studies by pre-administration of an excess of 
unlabeled PD153035 could not be demonstrated and an in-
crease (rather than a reduction) in the levels of activity up-
take in tissues was obtained [88]. In another study, PD153035 
was non-specifically labeled either at the 6- or 7-methoxy 
positions and its biodistribution using PET in rats bearing 
EGFR-rich SH-SY5Y human neuroblastoma xenografts, 
revealed a low maximum tumor activity-uptake value of 
~0.3% injected tracer dose per mL of tumor tissue (%ID/mL) 
at less than 10 min post injection [89]. At this time period, 
radioactivity uptakes in the gastrointestinal (GI) tract and in 
the liver were about 2 to 2.5-fold higher, resulting in high 
activity background levels. Moreover, specific tumor uptake 
was not confirmed in a blocking study. Derivatives of PD 
153035 were labeled with 
123I (t1/2 = 13.3 h), 
125I (t1/2 = 59.4 
d) and 
18F (t1/2 = 110 min.) (Fig. 4); however, specific bind-
ing of the labeled compounds to the EGFR was demon-
strated only in vitro using EGFR positive MDA-MB 468 
human breast cancer cells [90]. In a later report, the biodis-
tribution of 
123I-PD153035 analog was evaluated by a dy-
namic gamma camera scan in rats bearing subcutaneous 
xenografts of 13762 MAT rat mammary adenocarcinoma 
cells [91]. Although it remains unclear whether this cell line 
expresses the EGFR, maximal tumor activity uptake was 
obtained between 30 and 60 min post injection of the tracer, 
followed by a decrease to background tissue levels after 5 h. 
Quantification of the data was neither performed, nor was 
there any specific binding demonstrated in this study. 
  A radiosynthetic strategy has been developed for fluo-
rine-18 labelling of 6,7-disubstituted 4-anilinoquinazolines at 
the anilino moiety [92-94]. In general, it was based on the 
nucleophilic substitution of the nitro group of dinitrobenzene 
derivatives with fluorine-18, followed by reduction of the 
second nitro group to yield labeled aniline. Subsequently, the 
[
18F]-labeled aniline was coupled to the 6,7- disubstituted 4'-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3).  Preparation of 
64Cu-DOTA-cetuximab for PET imaging of EGFR-positive tumors. 
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chloroquinazoline moiety to furnish the final fluorine-18 
labeled compounds. This methodology was used for the for-
mation of several potential fluorine-18 labeled PET probes, 
derived from therapeutic agents such as erlotinib, gefitinib 
and ZD6474. [
18F]ML01 (Fig. 4) was one of the most studied 
compounds among these reversible labeled inhibitors. Its 
median inhibitory concentration (IC50) values in an enzyme-
linked immunosorbent assay (ELISA), using A431-derived 
cell membranes that overexpress the receptor, and in intact 
A431 cells were 0.2 nM and 3.8 nM, respectively. [
18F]- 
ML01 exhibited high specific binding and could accurately 
measure receptor content (Bmax) in intact A431 cells. In a 
study testing the kinetics of ML01 binding to EGFR, the 
association and dissociation-rate constants (Kon, Koff) were 
obtained, and a derived kD value of 65 nM, defined as Koff/ 
Kon, was calculated. According to the number of EGFR bind-
ing-sites per A431 cell [95-97], and assuming 10
9 cells per 
gram of tumor, an estimated Bmax value of 200 nM EGFR in 
the tumor tissue could be obtained, yielding a rather low 
binding potential (BP) of ~3. This could explain why al-
though ML01 exhibited significant inhibitory potency and 
adequate specific binding to the receptor in vitro, its in vivo 
performance was less promising. Indeed, PET-imaging of 
A431 tumor-bearing mice following I.V. administration of 
[
18F]-ML01 indicated that although tumor could be clearly 
detected, its visualization persisted for a narrow imaging 
time-frame of 8-12 min post injection. Thus, kinetic factors 
such as rapid dissociation from the receptor and elevated 
blood clearance rendered ML01 ineffective as a tracer for 
imaging the EGFR [94].  
  Gefitinib was labeled with fluorine-18 in a similar fash-
ion to ML01 [92]. In addition, the radiolabeling of gefitinib 
with carbon-11 at the C-7 methoxy group has also been re-
ported (Fig. 4) [98]. The first biological evaluation per-
formed with radiolabeled gefitinib was presented in 2003. 
The potential of the fluorine-18 labeled compound as an im-
aging agent was investigated by microPET studies; however, 
neither significant tumor uptake nor specific binding could 
be demonstrated [99]. These findings were supported by a 
recent and more detailed report [100] in which the microPET 
study did not show preferential activity uptake in tumors 
relative to surrounding skeletal muscle; furthermore, in all 
studied tumor types, the tumor: blood activity uptake ratio 
was < 1 during 2 h post injection of the tracer, and the ob-
tained binding potential (BP) was similar in EGFR positive 
and negative xenografts.  
  Although the above described labeled compounds are 
either identical to or derivatives of existing drugs, they have 
not yielded promising target-specific agents for PET tumor 
imaging since more prerequisites have to be fulfilled. It is of 
utmost importance that a tracer level administration of the 
imaging agent (as opposed to drug which can be adminis-
tered up to the maximum tolerated dose) furnishes high and 
specific accumulation in the target tissue. This tumor uptake 
should be significantly higher than in the surrounding tissue 
to yield elevated signal: noise ratio which is mandatory for 
imaging. Thus, favorable pharmacokinetics and minimum 
levels of radiolabeled metabolites are equally required for 
adequate imaging. Up till now, anilinoquinazoline-based 
radiolabeled reversible inhibitors, although generally exhibit-
ing high potential as imaging agents in vitro, they have not 
yielded adequate PET imaging of EGFR-overexpressing 
tumors in an animal model. This failure could be attributed 
to their elevated log P, fast blood clearance, rapid metabo-
lism, and binding competition between manifold higher lev-
els of intracellular ATP and the radioligand resulting in the 
rapid washout of the labeled inhibitor from the tumor. Sub-
sequently, attempts have been made for the development of 
irreversible inhibitors of the EGFR as potential imaging 
agents (Fig. 4) [101-111]. Out of the numerous developed 
labeled irreversible EGFR inhibitors, four were intensely 
studied as imaging agent candidates, i.e., [
11C]-ML03, [
11C] 
and [
18F]-ML04, [
18F]-FEQA and morpholino [
124I]-IPQA. In 
this category of irreversible EGFR PET agent candidates, the 
carbon-11 labeled 6-acrylamido-4-(3,4-dichloro-6-fluoroani- 
lino)quinazoline, ML03, (Fig. 4) was the first to be synthe-
sized and labeled [101, 103]. ML03 exhibited a remarkable 
inhibitory potency with an IC50 of 0.037 nM in a cell-free 
assay combined with sustained inhibition of the receptor in 
intact A431 cells; its specific binding to the receptor was 
demonstrated in a cell binding assay and also in tissue sec-
tions of liver and A431 tumors. However, its fast degrada-
tion in vivo in combination with low tumor activity uptake 
levels along with pronounced activity concentration in the 
liver, kidney and intestine, obtained in tumor-bearing rat 
biodistribution studies, rendered [
11C]-ML03 ineffective as a 
tracer for imaging of the EGFR [99]. In 2003, the prepara-
tion and biological evaluation of an additional labeled acry-
lamido-anilinoquinazoline derivative, N-{4-[3'-[
18F]fluoro- 
ethylphenyl)amino]-6-quinazolinyl}acrylamide ([
18F]-FEQA) 
was reported [112]. A dynamic microPET scan was per-
formed in A431 tumor-bearing mice in order to study tracer 
biodistribution. A rather low maximal tumor: blood activity 
uptake ratio of 0.12 was obtained shortly post administration 
of the tracer, which decreased over time. In contrast, a high 
activity uptake in metabolic and excretory organs was de-
tected as inferred by the relatively high tissue: blood activity 
uptake ratio that was obtained at further time points in the 
gallbladder and bladder, indicating rapid clearance of the 
labeled compound probably via both renal and hepatobiliary 
routes. Thus, although the tumor could be visualized, high 
levels of background activity were observed, and more im-
portantly, the EGFR specific tumor uptake was not evalu-
ated. Another interesting EGFR-TK PET agent is the (E)-
But-2-enedioic acid [4-(3-[
124I]iodoanilino)-quinazolin-6-yl]-
amide-(3-morpholin-4-yl-propyl)-amide (morpholino-[
124I]-
IPQA) (Fig. 4) [110]. It has a unique potential as a PET 
agent since it has shown for the first time selective and irre-
versible binding to the ATP-binding site of the activated 
(phosphorylated), but not to the inactivated EGFR kinase, 
thus having the ability to discriminate in vivo between these 
two forms of the receptor. In dynamic PET scans of rats 
bearing two xenografts, a gradual accumulation of the tracer 
in A431 (EGFR-positive), but not in human chronic myeloid 
leukemia K562 (EGFR-negative) tumors, was observed. 
However, only a moderate activity uptake value in the posi-
tive xenograft of ~0.72 a% id/ g tumor, at 1 h post injection 
of the tracer was obtained. Although this approach indicates, 
to some extent, specific uptake, more convincing evidence 
such as direct in vivo blocking studies would be required. 
The major drawbacks of morpholino-[
124I]-IPQA include 
low solubility, significant hepatobiliary clearance, and intes-
tinal reuptake.  Imaging of EGFR and EGFR Tyrosine Kinase Overexpression  Current Pharmaceutical Design, 2008, Vol. 14, No. 28    2991 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Labelled EGFR bioprobes. 
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Table 4.  ML04 is a Potent, Irreversible and Selective Inhibitor of the EGFR 
IC50 Values in Intact Cells [nM] 
a 
Investigated Tyrosine 
Kinase (Cell Line) 
Immediately after Removal of the Inhibitor  Eight Hours after Removal of the Inhibitor 
IC50 Values in a Cell-Free 
Kinase Assay [nM] 
a 
EGFR (A431)   4-10 
b    10-50 
b 
EGFR (MDA-MB 468)  1-5  1-5 
EGFR (PC10)  10-50  10-50 
EGFR (NCI-H1975)  25  ND 
EGFR (DHER14)   4 
b ND 
0.11 ± 0.08 
b 
HER2 (CSH12)  25-50 
b ND  ND 
PDGFR (NIHPDGFR)  > 1000 
b ND  ND 
VEGFR-2 (PAE/ KDR)  > 10,000  ND  ND 
c-Src ND  118  ± 26 
IGF-1R ND >  15,000 
a The median inhibitory concentrations (IC50) values were obtained from at least three independent experiments. Where applicable, results are presented as mean ± SD. 
b Studies investigating the inhibitory potency toward the EGFR and related tyrosine kinases were carried out using either intact cells or a cell free kinase assay.  
 ND: not determined. 
 
  Major progress with irreversible PET EGFR biomarkers 
has been achieved with the development of ML04 [109]. It 
demonstrated potent, irreversible inhibition of the EGFR in 
four human cell lines that express this receptor (Table 4). 
The comparable inhibition levels obtained both immediately 
after and 8 h after removal of the inhibitor from the medium 
suggest that ML04 binds to the EGFR covalently and indeed 
inhibits activation of the receptor in an irreversible manner. 
This cell-based assay was originally introduced by Fry and 
colleagues as an additional supporting indicator of irreversi-
ble bonding [113]; later, this methodology has been routinely 
used as a reliable criterion of irreversible inhibition [106, 
114, 115]. In addition, ML04 was found to selectively bind 
to the EGFR with a 250-fold inhibitory potency compared to 
other closely related tyrosine kinases with the exception of 
erbB2 which shares 80% homology with EGFR in its kinase 
domain (Table 4). Following injection of the compound to 
U87MG.wt EGFR tumor-bearing mice (5 mg/kg i.v.), ML04 
demonstrated significant inhibition of EGFR phosphoryla-
tion levels in tumors in vivo at different time points post ad-
ministration. As indicated in Fig. (5), significant inhibition 
of phosphorylation persisted for at least 6 h post administra-
tion of the inhibitor indicating that, indeed, the compound 
reached the tumor and penetrated the cancer cells in suffi-
cient quantity so as to bind to a relatively significant portion 
of the receptors for an extended period of time, as expected 
from irreversible inhibitors. The compound was successfully 
labeled either with carbon-11 on the dimethylamine moiety 
via  C-11 methylation reaction using C-11 methyl iodide 
[105] or with fluorine-18 at the anilino moiety via a multis-
tep radiosynthesis route [108]. In binding studies employing 
fluorine-18 ML04 and A431 cells, the compound demonstra-
ted high specific binding of approximately 75% and could 
accurately measure the number of EGFR molecules per cell. 
In addition and in contrast to ML03, the previously labeled 
irreversible inhibitor, ML04 was found to be stable in blood 
either in ex vivo or in vivo studies. In vivo biodistribution of 
the radiolabeled compound revealed higher activity uptake in 
EGFR-positive tumors as compared to previously studied 
EGFR PET imaging agent candidates, and a remarkable tu-
mor: blood and tumor: muscle activity uptake ratios of about 
7 and 5, respectively, three hours following administration of 
the radiotracer (Table 5). Nevertheless, only minor EGFR 
specific uptake of the compound was detected in vivo using 
EGFR-negative tumors or blocking studies as controls (Fig. 
6) [109]. A possible explanation of this observation could 
stem from the relatively high log P of ML04 which on the 
one hand, is required for cell penetration, while, on the other, 
it leads to high accumulation of the compound in the ex-
tracellular space of the tumor, resulting in high non-specific 
uptake. Therefore, derivatives of the compound such as 
ML09 [111], ML10 and ML11 (Fig. 4) which exhibit lower 
log P, yet not too low to enable cell penetration, have been 
developed and labeled with fluorine-18 via one step radio-
synthesis, Iodine-124 or carbon-11 (Scheme 1) and are cur-
rently under investigation (unpublished results). 
SUMMARY 
  In conclusion, the EGFR has been recognized as one of 
the most promising targets for the treatment of cancer. In-
deed, several drugs, either based on monoclonal antibodies 
targeting the extracellular domain of the receptor or small 
organic molecules targeting the tyrosine kinase domain, are 
FDA-approved and many others are in various stages of de-
velopment. However, the therapeutic potential of targeting 
the EGFR remains to be refined and optimized. Quantitative 
PET molecular imaging, coupled with selective labeled bio-
markers, may facilitate in vivo EGFR-targeted drug efficacy 
by noninvasively assessing expression of EGFR in tumor, 
guiding dose and regime by measuring target-drug binding, Imaging of EGFR and EGFR Tyrosine Kinase Overexpression  Current Pharmaceutical Design, 2008, Vol. 14, No. 28    2993 
receptor occupancy, and duration of inhibition, as well as 
potentially detecting the existence of a primary or secondary 
mutation leading to either drug interaction or failure of 
EGFR recognition by the drug. Two approaches have been 
undertaken for the development of EGFR PET imaging 
agents: labeling monoclonal antibodies and small organic 
molecules. These labeled compounds were based on either 
approved or drugs in the process of development. In the case 
of labeled monoclonal antibodies, Cetuximab has provided 
the most encouraging results by exhibiting high specificity 
and high accumulation in tumor, however, its slow clearance 
from the bloodstream and metabolic tissues results in limited 
imaging contrast at early time points post injection. There-
fore, the labeling of smaller antibody fragments may emerge 
in the near future. In the case of small organic molecules, the 
main hurdles to be overcome include excessive clearance 
from blood, nonspecific binding and inadequate pharma-
cokinetic properties. Even though some of these developed 
imaging agents were based on approved drugs, they did not 
yield adequate PET imaging. Based on these findings, it is 
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Tumors were excised at various time points after the administration of either ML04 (5 mg/ 
Kg) or vehicle to the mice, and the extent of EGFR phosphorylation in tumors was evaluated 
by Western Blot analysis. Sustained inhibition of the receptor in U87MG.wt EGFR tumors is 
obtained as long as 6 h after administration of ML04. Results are presented as the mean per-
centage of PY signal (normalized by the relative protein content of the sample) compared to 
the vehicle treated animals ± SD. 
Fig. (5). In vivo inhibition of phosphorylation of the EGFR in U87MG.wt EGFR xenografts is attained after administration of an 
excess of ML04 to mice.   
 
Table 5.  Biodistribution of [
18F]-ML04 3 h Post Administration to U87MG.wt EGFR Tumor-Bearing Mice 
Tissue  Percent of Injected Dose Per Gram of Organ (n=12)  Tumor: Tissue Activity Uptake Ratios (n=10) 
Blood  0.17 ± 0.02  7.07 ± 1.11 
Bone  0.40 ± 0.05  2.42 ± 0.12 
Heart  0.33 ± 0.02  3.07 ± 0.20 
Intestine  2.19 ± 0.14  0.46 ± 0.03 
Kidneys  3.98 ± 0.25  0.25 ± 0.02 
Liver  1.63 ± 0.09  0.59 ± 0.02 
Lungs  6.11 ± 0.50  0.16 ± 0.01 
Muscle  0.17 ± 0.03  6.07 ± 0.70 
Skin  0.59 ± 0.04  1.62 ± 0.05 
Spleen  2.70 ± 0.19  0.37 ± 0.02 
Stomach  0.94 ± 0.09  1.13 ± 0.09 
U87MG.wtEGFR tumor  0.99 ± 0.05    
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Tumor-bearing mice were injected with [
18F]-ML04 and sacrificed at the allotted time points. Tumors 
were excised, weighed, and measured for their radioactivity content in a gamma counter. The percent 
of injected dose per gram of tumor was calculated by correcting the activity concentration in the tu-
mor for the injected dose. Results are presented as mean ± SD; statistically significant differences are 
marked with an asterisk. 
Fig. (6).  Preferential uptake of [
18F]-ML04 in U87MG.wt EGFR over U138MG tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Labelling of ML09, ML10 and ML11. 
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evident that the properties of successful targeted drugs will 
not always lead to efficient tracer level imaging agents. In-
deed, important features should be taken into consideration 
when designing optimal imaging agents including, affinity, 
selectivity, stability, suitable Log p, optimal blood clearance, 
low uptake in non target tissues, and high specific binding in 
target tissues. Future trends in this investigation will proba-
bly focus on the development of labeled EGFR affibodies 
targeting the extracellular domain and labeled small organic 
molecules directed toward the intracellular substrate binding 
site rather than the ATP binding site. 
ABBREVIATIONS 
C225    =  Cetuximab 
CML   =  Chronic myelogenous leukemia 
CT   =  Computed tomography  
DOTA   =  1,4,7,10-  Tetraazacyclododecane-1,4,7,10-
tetraacetic acid 
DTPA   =  Diethylenetriaminepentaacetic acid  
ELISA   =  Enzyme-linked immunosorbent assay 
EGF   =  Epidermal growth factor  
EGFR   =  Epidermal growth factor receptor  
EOB   =  End of bombardment 
GIST   =  Gastrointestinal stromal tumors  
HCC   =  Hepatocellular carcinoma  
HER 2, 3, 4   =  Human EGFR 2, 3, 4 
IC50   =  Median inhibitory concentration 
% ID/g    =  Percentage of the injected dose measured 
per gram of tissue or organ  
IHC   =  Immunohistochemistry  
mM   =  Millimolar  
MRI   =  Magnetic resonance imaging  
nM   =  Nanomolar  
NSCLC   =  Non small cell lung cancer  
PDGFR   =  Platelet-derived growth factor receptors  
PET   =  Positron emission tomography 
PTKs   =  Protein tyrosine kinases  
PY   =  Phosphotyrosine  
RTK   =  Receptor tyrosine kinase  
SCCHN   =  Small cell carcinoma of the head and neck  
SPECT    =  Single-photon emission computed tomo-
graphy  
TK   =  Tyrosine kinase  
VEGFR   =  Vascular endothelial growth factor receptor  
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